ALK and non-small cell lung carcinoma: For example, NSCLC patients with EGFR mutations and ALK (Anaplastic lymphoma kinase) gene rearrangement will benefit from targeted therapy of EGFR-TKIs (Tyrosine kinase inhibitors) (such as erlotinib and afatinib)14 and ALK inhibitors (crizotinib, ceratinib, etc.)15, respectively.